Unc0631

KDM3A (ab91252, Abcam, Cambridge, MA, USA), Ki67 (ab16667, Abcam, Cambridge, MA, USA), E-cadherin (CST, #3195, Cell Signaling Technology, Danvers, MA, USA), Vimentin (CST, #5741, Cell Signaling Technology, Danvers, MA, USA), Hippo pathway antibody sampler kit (CST 8579, Cell Signaling Technology, Danvers, MA, USA), including LATS1, MST1, MST2, YAP1, TAZ, and GAPDH (sc-365062, Santa Cruz, CA, USA) were used in this study. H3K9m2 inhibitor Bix01294, UNC0631, Hippo pathway inhibitor verteporfin were purchased from Selleck (Houston, TX, USA).

Supplementary Figure 1 lists all small molecule compounds used in the screens. Selected epigenetic small molecule compounds were obtained from the Collaborative Research Centre 992 Medical Epigenetics (CRC992 MEDEP; Laboratory of Manfred Jung) at University of Freiburg, and from the Structural Genomics Consortium (SGC). Additionally, the following chemical compounds were obtained commercially: Bromosporine (Sigma #SML0992), Ex-527 (Selleckchem #S1541), MM-102 (Selleckchem #S7265), Mocetinostat (Selleckchem #S1122), OICR9429 (Tocris # 5267), PFI-3 (Selleckchem #S7315), UNC0631 (Selleckchem, S7610). All small molecule compounds were dissolved in DMSO (99.5%, PanReac AppliChem #A3672) at 10 mM concentration. For experiments, the 10 mM stock was diluted with E3 medium to obtain the desired working stock concentration of 60 µM containing 1% DMSO, which was used to prepare the dilution series. The γ-secretase inhibitor DAPT (increased DA neurogenesis; (Mahler et al., 2010 (link)); Sigma, #D5942) and the prodrug neurotoxin MPTP (neurotoxic to DA neurons; (Sallinen et al., 2009 (link)); Sigma #M0896) were used as positive controls for drug delivery into embryos and dopaminergic neurons.